NASDAQ: MRNA · Biotechnology

Moderna (MRNA) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Moderna (MRNA) at $185.21 a share. The stock last closed at $215.27, which puts the model's fair value 14.0% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Moderna, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$185.21midpoint of 2,000 simulations
Last close$215.27NASDAQ: MRNA
Gap to fair value-14.0%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $210.32 to $185.21 (-11.9%). The multiple the model anchors on moved, lowering the fair value: most of the move.

What the model makes of itThe price of $215.27 is 14.0% above it: Fairly valued, on a medium evidence grade.

What's nextNext report on 12 Feb 2027. Options prices imply a move of about 24% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give MRNA?

The calibrated range for MRNA over 63 trading days is $163.88 to $286.69. It sits around the last close, and its width comes from the volatility that MRNA's own options imply (83% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $129.02 to $255.28. In 33% of the simulations the fair value came out above the price the model ran on.

$81.71$416.57
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $185.21. Dashed line: the last close, $215.27.

Faircurve Insights · 14 Nov 2026

Moderna, Inc. is a biotechnology firm dedicated to the discovery, development and commercialisation of messenger RNA (mRNA) based therapies and preventive medicines.

On 14 Nov 2026, Faircurve's model put the fair value at $185.21 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $210.32, so the fair value moved -11.9%. The model says the multiple it anchors on moved, lowering the fair value: most of the move. The calibrated range over 63 trading days is $163.88 to $286.69, built from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade covers input completeness, the number and agreement of comparable companies, and the spread of outcomes. It does not say whether the fair value is right.

Moderna scores 37 out of 100 on the model's overall quality score, a composite of six factors scored against comparable companies. Earnings quality scores 100. Profitability scores 0, with ROIC at -29.8% against a peer median of 16.9%. Stability also scores 0, with five-year EBITDA margin downside volatility at 56.4 pts against a peer median of 4.5 pts. The model compares Moderna with Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Roivant Sciences Ltd., United Therapeutics Corporation and Incyte Corporation.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does MRNA report earnings, and how has the stock reacted?

Moderna's next earnings report is scheduled for 12 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 11.1% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. MRNA's 30 day implied volatility works out to about 23.9% over one month.

Around its last 2 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across MRNA's last 8 reports, ignoring direction, was 4.5%.

0%5%10%15%20%12.4%1.6%5 Nov '2615.4%11.4%6 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

Earlier reports are left out: the options record is on a different share basis.

What the options market has priced for a month's move in MRNA

15%20%25%30%35%6 Nov '26 report5 Nov '26 report24% at 16 Nov '2621 Aug '2616 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 29% on 21 Aug 2026, reached 33% on 16 Oct 2026 and reads 24% on 16 Nov 2026. The marks are report dates.

How does MRNA score on business quality?

Moderna's overall quality score is 37 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.0-29.8%ROIC16.9%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).100
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.37-39.2%Revenue growth, trailing2.4%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.290.0%Net buybacks / market value0.9%
Balance sheetNet debt to EBITDA and interest coverage.70-1.22xNet debt / EBITDA1.28x
StabilityDownside volatility of the EBITDA margin over the last five years.056.4 ptsEBITDA margin downside volatility, 5y4.5 pts

How does MRNA compare with similar companies?

The companies in biotechnology closest to Moderna in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
REGN Regeneron Pharmaceuticals, Inc.$952.40$997.74+4.8%Fairly valued
VRTX Vertex Pharmaceuticals Incorporated$537.79$508.20-5.5%Fairly valued
ROIV Roivant Sciences Ltd.$38.61$26.96-30.2%Overvalued
INSM Insmed Incorporated$122.88$113.05-8.0%Low evidence grade
UTHR United Therapeutics Corporation$587.88$601.98+2.4%Fairly valued
INCY Incyte Corporation$120.27$136.90+13.8%Fairly valued
ALNY Alnylam Pharmaceuticals, Inc.$159.73$165.54+3.6%Low evidence grade
EXEL Exelixis, Inc.$67.10$68.00+1.3%Low evidence grade

What the comparable companies' multiples alone would give for MRNA, the peer-implied price, is $24.02 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

Moderna at a glance

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines.

Market value
$90.4B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$2.6B
Consensus revenue growth, next fiscal year
+17.8%
Analysts with estimates
15
Beta to the US market
1.91
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. MRNA was not among them.

How the fair value is worked out: the model prices Moderna on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for MRNA was $210.32. As of 14 Nov 2026 it is $185.21, a change of -11.9%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Moderna's valuation

Is Moderna stock undervalued or overvalued?

On Faircurve's model, MRNA reads as Fairly valued as of 14 Nov 2026. The model's fair value is $185.21 a share against a last close of $215.27, a gap of -14.0%.

What is MRNA's fair value?

$185.21 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $129.02 to $255.28.

What price range does the model give MRNA?

$163.88 to $286.69 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Moderna report earnings next?

The next report is scheduled for 12 Feb 2027. Companies can move their dates.

How much has MRNA moved on past earnings reports?

Across its last 8 reports the median two session move was 4.5%, ignoring direction. The largest was +11.4% around the report of 6 Nov 2026.

How confident is the model in this valuation?

The model's evidence grade for MRNA is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on MRNA

The model holds no idea open on MRNA today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on MRNA with their outcomes. A free account is enough.

Keep reading